

Cover Story
Guest Editorial
Over and over again, I’ve seen the same missteps, clumsy excuses, and faulty logic during sponsor presentations to the FDA Oncologic Drugs Advisory Committee, repeated as if part of a tragic, regulatory update to the movie Groundhog Day.
In Brief


Clinical Roundup


Drugs & Targets


Trending Stories
- Mikaela Naylon Give Kids a Chance Act nixed by Senate
- Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program
- Otis Brawley looks back on a year of great science and greater challenges
- Twitter star Vinay Prasad retires @VinayPrasadMD
- AI will determine Medicare prior authorizations in six states under new pilot program
- GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation














